• 2024-06-11

BostonGene and Collaborators Honored with GRASP Advocate Choice Award at the 2024 ASCO Annual Meeting

Study Demonstrates the Critical Role of Tumor Microenvironment Profiling in Developing Personalized Treatments

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the presentation of its poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting has received the GRASP Advocate Choice Award. The poster details the results of a study that uncovered the intricate heterogeneity of the tumor microenvironment (TME) in invasive lobular carcinoma (ILC) of the breast, through bulk RNA-seq and spatial biology analyses, highlighting the importance of TME profiling in developing personalized treatments for ILC patients.

GRASP (Guiding Researchers and Advocates to Scientific Partnerships) is a nonprofit, patient-led organization that connects patients, clinicians and researchers to exchange ideas and make faster progress in improving treatments and ending cancer. Founded in 2019 by two breast cancer survivors and advocates, GRASP aims to break down silos and foster connections within the cancer community. The 2024 GRASP event will be held in conjunction with the ASCO Annual Meeting on June 12-13, 2024.

The study, "The Multiomic Tumor Microenvironment Landscape of Invasive Lobular Carcinoma of the Breast," was presented by Jason Mouabbi, MD, assistant professor of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center. This research is a collaborative effort between BostonGene and MD Anderson.

The findings revealed 13 primary cell populations and 25 distinct immune and stromal cell subtypes within the TME of ILC. It demonstrated concordance between RNA-seq profiles and spatial biology characteristics, revealing notable differences among various subtypes in RNA and multiplex immunofluorescence (MxIF) data. This multiomic approach provides a baseline for understanding the nuances of the TME in ILC, highlighting unique opportunities for developing novel therapies and combinations.

"Receiving this award is a testament to our dedication to cancer research and advancing patient care through innovative solutions," said Krystle Nomie, PhD, VP of Research Partnerships at BostonGene. "Our collaborative efforts in TME profiling are vital in unraveling the complexities of ILC and tailoring personalized treatments for patients."


About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin O’Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com